SEC Form 4 · accession 0001684532-26-000005
Fulgent Genetics, Inc. · FLGT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Hanlin Gao
Officer — Chief Scientific Officer
Period of report
Jun 2, 2026
Accepted (ET)
Jun 3, 2026 · 5:29 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001674930
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 2, 2026 | S | 1,688 | $17.8855 | D | 990,374 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025.
- F2The shares were sold in multiple transactions at prices ranging from $17.63 to $18.10, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.